172 related articles for article (PubMed ID: 21669246)
1. Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity.
Mizuno D; Kimoto T; Takei T; Fukuta A; Shinahara W; Takahashi E; Yano M; Kido H
Vaccine; 2011 Jul; 29(33):5368-78. PubMed ID: 21669246
[TBL] [Abstract][Full Text] [Related]
2. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
[TBL] [Abstract][Full Text] [Related]
3. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
6. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
Madhun AS; Haaheim LR; Nøstbakken JK; Ebensen T; Chichester J; Yusibov V; Guzman CA; Cox RJ
Vaccine; 2011 Jul; 29(31):4973-82. PubMed ID: 21600260
[TBL] [Abstract][Full Text] [Related]
7. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
[TBL] [Abstract][Full Text] [Related]
8. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
10. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
12. Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses.
Kimoto T; Mizuno D; Takei T; Kunimi T; Ono S; Sakai S; Kido H
Influenza Other Respir Viruses; 2013 Nov; 7(6):1218-26. PubMed ID: 23710832
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
[TBL] [Abstract][Full Text] [Related]
14. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
[TBL] [Abstract][Full Text] [Related]
15. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
Arulanandam BP; O'Toole M; Metzger DW
J Infect Dis; 1999 Oct; 180(4):940-9. PubMed ID: 10479116
[TBL] [Abstract][Full Text] [Related]
16. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
17. Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs.
Nishino M; Mizuno D; Kimoto T; Shinahara W; Fukuta A; Takei T; Sumida K; Kitamura S; Shiota H; Kido H
Vaccine; 2009 Sep; 27(41):5620-7. PubMed ID: 19647064
[TBL] [Abstract][Full Text] [Related]
18. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice.
Kimoto T; Kim H; Sakai S; Takahashi E; Kido H
Vaccine; 2019 Jan; 37(4):612-622. PubMed ID: 30553569
[TBL] [Abstract][Full Text] [Related]
19. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ
Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171
[TBL] [Abstract][Full Text] [Related]
20. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
Saluja V; Visser MR; Ter Veer W; van Roosmalen ML; Leenhouts K; Hinrichs WL; Huckriede A; Frijlink HW
Vaccine; 2010 Nov; 28(50):7963-9. PubMed ID: 20946860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]